Literature DB >> 20632131

Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers.

Thomas J Montine1, Elaine R Peskind, Joseph F Quinn, Angela M Wilson, Kathleen S Montine, Douglas Galasko.   

Abstract

Alzheimer's disease (AD) is a common age-related chronic illness with latent, prodrome, and fully symptomatic dementia stages. Increased free radical injury to regions of brain is one feature of prodrome and dementia stages of AD; however, it also is associated with advancing age. This raises the possibility that age-related free radical injury to brain might be caused in part or in full by latent AD. We quantified free radical injury in the central nervous system with cerebrospinal fluid (CSF) F(2)-isoprostanes (IsoPs) in 421 clinically normal individuals and observed a significant increase over the adult human lifespan (P < 0.001). Using CSF amyloid (A) β(42) and tau, we defined normality using results from 28 clinically normal individuals <50 years old, and then stratified 74 clinically normal subjects ≥60 years into those with CSF that had normal CSF Aβ(42) and tau (n = 37); abnormal CSF Aβ(42) and tau, the biomarker signature of AD (n = 24); decreased Aβ(42) only (n = 4); or increased tau only (n = 9). Increased CSF F(2)-IsoPs were present in clinically normal subjects with the biomarker signature of AD (P < 0.05) and those subjects with increased CSF tau (P < 0.001). Finally, we analyzed the relationship between age and CSF F(2)-IsoPs for those clinically normal adults with normal CSF (n = 37) and those with abnormal CSF Aβ(42) and/or tau (n = 37); only those with normal CSF demonstrated a significant increase with age (P < 0.01). These results show that CSF F(2)-IsoPs increased across the human lifespan and that this age-related increase in free radical injury to brain persisted after culling those with laboratory evidence of latent AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20632131      PMCID: PMC3000441          DOI: 10.1007/s12017-010-8126-6

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  39 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Safety and acceptability of the research lumbar puncture.

Authors:  Elaine R Peskind; Robert Riekse; Joseph F Quinn; Jeffrey Kaye; Christopher M Clark; Martin R Farlow; Charles Decarli; Charles Chabal; Darcy Vavrek; Murray A Raskind; Douglas Galasko
Journal:  Alzheimer Dis Assoc Disord       Date:  2005 Oct-Dec       Impact factor: 2.703

3.  Memory improvement following induced hyperinsulinemia in Alzheimer's disease.

Authors:  S Craft; J Newcomer; S Kanne; S Dagogo-Jack; P Cryer; Y Sheline; J Luby; A Dagogo-Jack; A Alderson
Journal:  Neurobiol Aging       Date:  1996 Jan-Feb       Impact factor: 4.673

Review 4.  F2-isoprostanes in Alzheimer and other neurodegenerative diseases.

Authors:  Thomas J Montine; Kathleen S Montine; Wendy McMahan; William R Markesbery; Joseph F Quinn; Jason D Morrow
Journal:  Antioxid Redox Signal       Date:  2005 Jan-Feb       Impact factor: 8.401

5.  Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.

Authors:  C D Smith; J M Carney; P E Starke-Reed; C N Oliver; E R Stadtman; R A Floyd; W R Markesbery
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

6.  AD lesions and infarcts in demented and non-demented Japanese-American men.

Authors:  Helen Petrovitch; G Webster Ross; Sandra C Steinhorn; Robert D Abbott; William Markesbery; Daron Davis; James Nelson; John Hardman; Kamal Masaki; Margaret R Vogt; Lenore Launer; Lon R White
Journal:  Ann Neurol       Date:  2005-01       Impact factor: 10.422

7.  Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.

Authors:  Randy L Buckner; Abraham Z Snyder; Benjamin J Shannon; Gina LaRossa; Rimmon Sachs; Anthony F Fotenos; Yvette I Sheline; William E Klunk; Chester A Mathis; John C Morris; Mark A Mintun
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

8.  Suppression of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate immune response in vivo by alpha- or gamma-tocopherol.

Authors:  Dejan Milatovic; Mike VanRollins; Ke Li; Kathleen S Montine; Thomas J Montine
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-04-19       Impact factor: 3.205

9.  Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease.

Authors:  Joseph F Quinn; Kathleen S Montine; Milar Moore; Jason D Morrow; Jeffrey A Kaye; Thomas J Montine
Journal:  J Alzheimers Dis       Date:  2004-02       Impact factor: 4.472

10.  Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease.

Authors:  T J Montine; W R Markesbery; J D Morrow; L J Roberts
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

View more
  29 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Unusual kinetic isotope effects of deuterium reinforced polyunsaturated fatty acids in tocopherol-mediated free radical chain oxidations.

Authors:  Connor R Lamberson; Libin Xu; Hubert Muchalski; J Rafael Montenegro-Burke; Vadim V Shmanai; Andrei V Bekish; John A McLean; Catherine F Clarke; Mikhail S Shchepinov; Ned A Porter
Journal:  J Am Chem Soc       Date:  2014-01-08       Impact factor: 15.419

3.  Obesity, age, and oxidative stress in middle-aged and older women.

Authors:  Tsogzolmaa Dorjgochoo; Yu-Tang Gao; Wong-Ho Chow; Xiao-Ou Shu; Gong Yang; Quiyin Cai; Nathaniel Rothman; Hui Cai; Honglan Li; Xinqing Deng; Martha J Shrubsole; Harvey Murff; Ginger Milne; Wei Zheng; Qi Dai
Journal:  Antioxid Redox Signal       Date:  2011-03-21       Impact factor: 8.401

4.  Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment.

Authors:  Jennifer L Bayer-Carter; Pattie S Green; Thomas J Montine; Brian VanFossen; Laura D Baker; G Stennis Watson; Laura M Bonner; Maureen Callaghan; James B Leverenz; Brooke K Walter; Elaine Tsai; Stephen R Plymate; Nadia Postupna; Charles W Wilkinson; Jing Zhang; Johanna Lampe; Steven E Kahn; Suzanne Craft
Journal:  Arch Neurol       Date:  2011-06

Review 5.  Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment.

Authors:  Luis F Gonzalez-Cuyar; Joshua A Sonnen; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

6.  Fine Particulate Matter Exposure and Cerebrospinal Fluid Markers of Vascular Injury.

Authors:  Rachel M Shaffer; Lianne Sheppard; Elaine R Peskind; Jing Zhang; Sara D Adar; Ge Li
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 7.  Gaps in Aging Research as it Applies to Rheumatologic Clinical Care.

Authors:  Una E Makris; Devyani Misra; Raymond Yung
Journal:  Clin Geriatr Med       Date:  2016-10-18       Impact factor: 3.076

8.  The association of serum trans-nonachlor levels with atherosclerosis.

Authors:  Lee C Mangum; Lauren H Mangum; Janice E Chambers; Matthew K Ross; Edward C Meek; Robert W Wills; J Allen Crow
Journal:  J Toxicol Environ Health A       Date:  2016-03-08

9.  Expression of Iron Transporters and Pathological Hallmarks of Parkinson's and Alzheimer's Diseases in the Brain of Young, Adult, and Aged Rats.

Authors:  Li-Na Lu; Zhong-Ming Qian; Ka-Chun Wu; Wing-Ho Yung; Ya Ke
Journal:  Mol Neurobiol       Date:  2016-08-30       Impact factor: 5.590

Review 10.  Markers of oxidant stress that are clinically relevant in aging and age-related disease.

Authors:  Kimberly D Jacob; Nicole Noren Hooten; Andrzej R Trzeciak; Michele K Evans
Journal:  Mech Ageing Dev       Date:  2013-02-18       Impact factor: 5.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.